In a release on May 25, Moderna says its vaccine is safe and effective among children ages 12 to 18.
The company reported results from its combined Phase 2 and 3 study involving more than 3,700 adolescents who were randomly assigned to receive both two doses of their COVID-19 vaccine and two doses of placebo. The study was designed to compare the results among adolescents to those among adults, which led to the company’s current emergency use authorization for its vaccine. Researchers are trying to see if the results among teens are at least as good, and not worse, than those of adults.
And that’s what society has reported. There were no reported cases of COVID-19 14 days after adolescent study participants received two doses of the stroke, compared with four cases among those who received a placebo, meaning that the vaccine was 100% effective. in protection against diseases. The company said the vaccine was also 93% effective in also protecting a symptom of COVID-19 disease after a dose.
Modern is the second company to report the results of COVID-19 vaccination among adolescents; March, Pfizer-BioNTech reported similar safety and efficacy of 100% in their study and reception authorization from the FDA for his two-dose shot among teenagers in May. Both Modern and Pfizer-BioNTech vaccines are built on mRNA technology, which involves the use of genetic material from the COVID-19 virus to train the immune system to fight it.
Modern plans to transmit the latest data from adolescence to the U.S. Food and Drug Administration to extend the current authorization for its vaccine to 12-year-old children.